BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 12, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Lyxumia lixisenatide: Phase III data

Top-line data from the double-blind, international Phase III GetGoal-M trial in 680 Type II diabetics inadequately controlled with metformin showed that morning and evening dosing of Lyxumia as an add-on to metformin each met the primary endpoint of significantly reducing HbA1c from baseline to week 24 vs. placebo plus metformin (p<0.0001 for both). On secondary endpoints, both dosing groups of Lyxumia significantly reduced FPG vs. placebo (p<0.005 for both). Additionally, a significantly greater proportion of...

Read the full 353 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >